De Yun Wang1, Aloke Gopal Ghoshal2, Abdul Razak Bin Abdul Muttalif3, Horng-Chyuan Lin4, Sanguansak Thanaviratananich5, Shalini Bagga6, Rab Faruqi6, Shiva Sajjan6, Alan J M Brnabic7, Francis C Dehle7, Sang-Heon Cho8. 1. Department of Otolaryngology, National University of Singapore, Singapore. 2. National Allergy Asthma Bronchitis Institute, Kolkata, India. 3. Institute of Respiratory Medicine, Kuala Lumpur, Malaysia. 4. Division of Thoracic Medicine, Chang Gung Memorial Hospital, Taoyuan City, Taiwan. 5. Department of Otorhinolaryngology, Khon Kaen University, Khon Kaen, Thailand. 6. Merck & Co., Inc. Kenilworth, NJ, USA. 7. Optum, Sydney, NSW, Australia. 8. Division of Asthma, Allergy and Clinical Immunology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea. Electronic address: shcho@plaza.snu.ac.kr.
Abstract
OBJECTIVES: Asia-Pacific Burden of Respiratory Diseases is a cross-sectional, observational study examining the burden of disease in adults with respiratory diseases across six countries. The aim of this study was to describe health care resource use (HCRU), work impairment, cost burden, and health-related quality of life (HRQOL) associated with respiratory disease in the Asia-Pacific. METHODS: Consecutive participants aged 18 years or older with a primary diagnosis of asthma, allergic rhinitis, chronic obstructive pulmonary disease, or rhinosinusitis were enrolled. Participants completed a survey detailing respiratory symptoms, HCRU, work productivity and activity impairment, and HRQOL. Locally sourced unit costs for each country were used in the calculation of total costs. RESULTS: The study enrolled 5250 patients. Overall, the mean annual cost for patients with a respiratory disease was US $4191 (SGD 8489) per patient. For patients who reported impairment at work, the mean annual cost was US $7315 (SGD 10,244), with productivity loss being the highest cost component for all four diseases (US $6310 [SGD 9100]). On average, patients were impaired for one-third of their time at work and 5% of their work time missed because of respiratory disease, which resulted in a 36% reduction in productivity. Patients with a primary diagnosis of chronic obstructive pulmonary disease had the greatest impact on HRQOL. CONCLUSIONS: In the Asia-Pacific, respiratory diseases have a significant impact on HCRU and associated costs, along with work productivity. Timely and effective management of these diseases has the potential to reduce disease burden and health care costs and improve work productivity and HRQOL. Copyright Â
OBJECTIVES: Asia-Pacific Burden of Respiratory Diseases is a cross-sectional, observational study examining the burden of disease in adults with respiratory diseases across six countries. The aim of this study was to describe health care resource use (HCRU), work impairment, cost burden, and health-related quality of life (HRQOL) associated with respiratory disease in the Asia-Pacific. METHODS: Consecutive participants aged 18 years or older with a primary diagnosis of asthma, allergic rhinitis, chronic obstructive pulmonary disease, or rhinosinusitis were enrolled. Participants completed a survey detailing respiratory symptoms, HCRU, work productivity and activity impairment, and HRQOL. Locally sourced unit costs for each country were used in the calculation of total costs. RESULTS: The study enrolled 5250 patients. Overall, the mean annual cost for patients with a respiratory disease was US $4191 (SGD 8489) per patient. For patients who reported impairment at work, the mean annual cost was US $7315 (SGD 10,244), with productivity loss being the highest cost component for all four diseases (US $6310 [SGD 9100]). On average, patients were impaired for one-third of their time at work and 5% of their work time missed because of respiratory disease, which resulted in a 36% reduction in productivity. Patients with a primary diagnosis of chronic obstructive pulmonary disease had the greatest impact on HRQOL. CONCLUSIONS: In the Asia-Pacific, respiratory diseases have a significant impact on HCRU and associated costs, along with work productivity. Timely and effective management of these diseases has the potential to reduce disease burden and health care costs and improve work productivity and HRQOL. Copyright Â
Authors: Horng-Chyuan Lin; Sang-Heon Cho; Aloke Gopal Ghoshal; Abdul Razak Bin Abdul Muttalif; Sanguansak Thanaviratananich; Shalini Bagga; Rab Faruqi; Shiva Sajjan; Camilla L Cahill; Kim K Hamrosi; De Yun Wang Journal: Medicine (Baltimore) Date: 2016-07 Impact factor: 1.889
Authors: Kwang Ha Yoo; Hae Ryun Ahn; Jae Kyoung Park; Jong Woong Kim; Gui Hyun Nam; Soon Kwan Hong; Mee Ja Kim; Aloke Gopal Ghoshal; Abdul Razak Bin Abdul Muttalif; Horng Chyuan Lin; Sanguansak Thanaviratananich; Shalini Bagga; Rab Faruqi; Shiva Sajjan; Santwona Baidya; De Yun Wang; Sang Heon Cho Journal: Allergy Asthma Immunol Res Date: 2016-11 Impact factor: 5.764
Authors: Jeong-Hui Park; Myong-Won Seo; Hyun Chul Jung; Jong-Kook Song; Jung-Min Lee Journal: Int J Environ Res Public Health Date: 2021-06-21 Impact factor: 3.390